Apollomics Inc. (NASDAQ:APLM – Get Free Report) traded down 1.7% during mid-day trading on Wednesday . The stock traded as low as $17.25 and last traded at $17.28. 419,490 shares changed hands during mid-day trading, an increase of 1,433% from the average session volume of 27,359 shares. The stock had previously closed at $17.58.
Analysts Set New Price Targets
Separately, Weiss Ratings cut shares of Apollomics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 28th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.
Get Our Latest Stock Report on Apollomics
Apollomics Stock Up 3.5%
Hedge Funds Weigh In On Apollomics
An institutional investor recently bought a new stake in Apollomics stock. Kestra Advisory Services LLC acquired a new stake in shares of Apollomics Inc. (NASDAQ:APLM – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 4,380 shares of the company’s stock, valued at approximately $82,000. Kestra Advisory Services LLC owned 0.40% of Apollomics as of its most recent filing with the Securities & Exchange Commission. 19.13% of the stock is currently owned by hedge funds and other institutional investors.
About Apollomics
Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.
Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.
See Also
- Five stocks we like better than Apollomics
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Apollomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollomics and related companies with MarketBeat.com's FREE daily email newsletter.
